That is basically what I was saying. If approved for all indications including icu and oncology we are really looking good. But the FDA can be fickle. The trial was for hemodialysis only. FDA can either:
1. Approve for all indications with broad label. (Best case for shareholders.)
2. Approve for all indications with an ongoing phase IV for oncology.
3. Approve hemo only and require phase III for oncology. In this case, oncology could use, but CRMD can't technically market to them and the label would technically be for hemodialysis only.
4. Screw us and require another phase III. (IMO, this is unlikely).
We get the biggest pop with #1, we get crushed with #4. I think 2 and 3 are most likely in my humble opinion.
2 and 3 still have huge upside, I just wouldn't bet on a near term $25 PPS right now is all.
Everything above are just my opinions. Good luck to all!!
News 
Market Data 
Discover 
